Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Gastric Cancer Market?

In the past few years, the gastric cancer market has seen exponential growth. The market, which is estimated to be worth $3.17 billion in 2024, is projected to increase to $3.64 billion in 2025 with a compound annual growth rate (CAGR) of 14.8%. The expansion observed in the historical era is attributable to an aging population, heightened health conscious behavior, growth in genetic mutations, a surge in unhealthy lifestyle practices, and an increase in cancer awareness.

In the coming years, the market size for gastric cancer is projected to experience quick expansion. It is anticipated to reach $6.37 billion in 2029, with a compound annual growth rate (CAGR) of 15.0%. The hike during the forecasted period could be due to factors such as increased obesity rates, comprehensive government initiatives, heightened investments in healthcare, growing demand for oral medications, and an uptick in cancer treatment facilities. Key trends for the forecast period involve combination chemotherapy, product enlargement, robotic-assisted surgeries, targeted treatments, strategic partnerships, and cutting-edge diagnostic instruments.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Gastric Cancer Market?

Increasing rates of obesity globally are predicted to stimulate the expansion of the gastric cancer market. Classified by a BMI (body mass index) of 30 or higher, obesity is a health condition marked by the excessive accumulation of body fat. It may cause a myriad of health complications and is on the rise due to factors such as unhealthy diet, sedentary behavior, environmental factors, insufficient physical exercise, and genetic predispositions. Notably, excessive body fat, especially visceral fat around the abdomen, increases the risk of stomach cancer because it triggers persistent inflammation and metabolic imbalances, which are both linked to cancer onset. This, in turn, boosts the demand for treatments for stomach cancer. As an example, in March 2024, the Switzerland-based intergovernmental body, the World Health Organization, reported that approximately 1 in 8 people worldwide had obesity in 2022. This figure included 2.5 billion adults aged 18 and up who were branded as overweight, with 890 million of those having obesity. Among adults, 43% were described as overweight and 16% as obese. Also, 37 million children below the age of 5 were overweight, and over 390 million children and adolescents between the ages of 5 and 19 were overweight, with 160 million of these being obese. Consequently, the upsurge in obesity rates is propelling the stomach cancer market.

What Are The Key Segment Trends Observed In The Gastric Cancer Market?

The gastric cancermarket covered in this report is segmented –

1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types

2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis

3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments

4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels

Subsegments:

1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma

2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma

3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST

4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3

5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors

Which Disruptive Trends Are Driving Change Across The Gastric Cancer Market?

Leading firms active in the gastric cancer market are investing in the creation of cutting-edge solutions, such as companion diagnostic assays, to enable personalized treatment. Companion diagnostic assays are tests designed to find patients who stand to benefit the most from a particular therapy, depending on the existence of specific biomarkers. For illustration, F. Hoffmann-La Roche Ltd., a pharmaceutical company hailing from Switzerland, announced in October 2024 that it had received approval by the U.S. Food and Drug Administration (FDA) for its VENTANA CLDN18 (43-14A) RxDx Assay. This assay is the first immunohistochemistry (IHC) companion diagnostic for evaluating CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. It helps identify those suitable for targeted VYLOY (zolbetuximab) treatment by measuring types of the CLDN18 protein, primarily CLDN18.2. Employing the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, this test enhances personalized healthcare and widens the treatment scope for gastric and GEJ adenocarcinoma.

Who Are The Leading Companies Driving The Gastric Cancer Market?

Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

Which Region Is Forecasted To Lead The Gastric Cancer Market In The Coming Years?

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Market 2025, By The Business Research Company

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Drugs Global Market 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market

Gastric Volvulus Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model